Journal: Frontiers in Pharmacology
Article Title: Identify the therapeutic role and potential mechanism of α-cyperone in diminished ovarian reserve based on network pharmacology, molecular docking, Lip-MS and experimental validation
doi: 10.3389/fphar.2025.1658536
Figure Lengend Snippet: Effect of AC on target proteins. The mRNA expression levels of MAP2K1 (A) , GSK3B (B) , MAPK14 (C) , SRC (D) , AKT1 (E) , ESR2 (F) , ERBB2 (G) , CDH1 (H) , CYP19A1 (I) , ESR1 (J) , MAPK8 (K) , PARP1 (L) . AC treatment is able to reverse the abnormal gene expression of GSK3B, MAPK14, AKT1, ESR2, ERBB2, CYP19A1 and MAPK8 in the CTX group. NC: normal control, CTX: cyclophosphamide, AC: α-Cyperone, ns: P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Article Snippet: Upon reaching approximately 80% confluency and displaying favorable condition, the cells were divided into three groups (n = 6 wells per group, three independent passages on different days): The normal control (NC group): complete medium only; CTX model (CTX group): 10 μg/mL cyclophosphamide (Sigma, C3250000) dissolved in serum-free DMEM; α-Cyperone (AC group): pre-treated with varying concentrations α-Cyperone (MedChemExpress, HY-N0710) for 6 h, followed by 10 μg/mL CTX without wash-out.
Techniques: Expressing, Gene Expression, Control